December 13th, 2022
Optieum Biotechnologies Inc
www.optieumbio.com
Announcement of Research License and Option Agreement with GI CELL
Optieum Biotechnologies Inc., and GI CELL (HQ: Seongnam, Korea / CEO: Dr. Chun Pyo Hong) haveentered into a Research License and Option Agreement for development of chimeric antigen receptor(CAR)-NK Cell Therapies.
The Research License and Option Agreement will aim to generate novel CAR-NK cells with GI CELL’s
CAR-NK technology platform and Optieum’s novel scFv antibodies against hematological tumor targets.
Optieum Biotechnologies has a proprietary platform to identify functional scFv/CAR constructs thatenhance therapeutic efficacy against targets of interest. Whereas, GI CELL has developed an NKPURE
Expander® platform that generates superior NK cells with high efficiency, safety, as well asmanufacturability.
Under the terms of the agreement, GI CELL will receive a license option. Upon exercise of the option,
Optieum will receive an upfront exercise fee and payments upon successful achievement of certain clinicaldevelopment milestones in the future. In addition, Optieum is eligible to receive royalties on future salesof products that arise from the license.
“We are pleased to enter this collaboration with Optieum Biotechnologies as we continue unlocking thefull potential of our NKPURE Expander® platform,” said Dr. Chun Pyo Hong, CEO of GI CELL. “We lookforward to evaluating the scFv antibodies from Optieum Biotechnologies’ discovery platform, which havethe potential to accelerate the development of our novel CAR-NK cells.”“We have been dedicated to expanding the toolbox to enable immune cell-based therapies in cancer
treatment, through our proprietary Eumbody System. Optieum Biotechnologies’ strength in discovery offunctional and improved scFvs in conjunction with GI CELL’s expertise in NK cell engineering andmanufacturing may lead to a generation of promising cellular immunotherapy for unmet medical needs,”
said Shun Nishioka, CEO of Optieum Biotechnologies.

About GI CELLGI CELL is a biotechnology company that drives research and development of novel immune cell-based
therapies with innovative technologies. Using its proprietary Immune Cell PURE Expander® platform forhighly potent NK and T cell development, GI CELL has integrated its ancillary material screening andcell expansion technologies to streamline the entire cell product development process. The Company isadvancing its allogenic NK cell therapies to transform the treatment paradigm for patients withhematological malignancies and solid tumors. GI CELL has multiple NK cell product candidates in INDenabling and preclinical development.
For more information, please visit https://www.gi-cell.com/en/.
About Optieum Biotechnologies
Optieum Biotechnologies is a biotechnology company with a platform engine to elicit functional andimproved scFvs for CAR-T cell and CAR-NK therapies with superior anti-tumor toxicity and persistence.
Optieum Biotechnologies’ scFv generation platform, Eumbody System, enables to acquire the scFv fromthe CAR-T cell’s functionality perspective rather than conventional binding affinity approach. Thecompany is advancing multiple CAR-T cell product candidates targeting hematological malignancies andsolid tumors which demonstrate significantly improved anti-tumor toxicity, proliferation capacity andmitigated antigen depletion.
For more information, please visit https://optieumbio.com/